» Articles » PMID: 29270136

Methodological Flaws, Conflicts of Interest, and Scientific Fallacies: Implications for the Evaluation of Antidepressants' Efficacy and Harm

Overview
Specialty Psychiatry
Date 2017 Dec 23
PMID 29270136
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In current psychiatric practice, antidepressants are widely and with ever-increasing frequency prescribed to patients. However, several scientific biases obfuscate estimates of antidepressants' efficacy and harm, and these are barely recognized in treatment guidelines. The aim of this mini-review is to critically evaluate the efficacy and harm of antidepressants for acute and maintenance treatment with respect to systematic biases related to industry funding and trial methodology.

Methods: Narrative review based on a comprehensive search of the literature.

Results: It is shown that the pooled efficacy of antidepressants is weak and below the threshold of a minimally clinically important change once publication and reporting biases are considered. Moreover, the small mean difference in symptom reductions relative to placebo is possibly attributable to observer effects in unblinded assessors and patient expectancies. With respect to trial dropout rates, a hard outcome not subjected to observer bias, no difference was observed between antidepressants and placebo. The discontinuation trials on the efficacy of antidepressants in maintenance therapy are systematically flawed, because in these studies, spontaneous remitters are excluded, whereas half of all patients who remitted on antidepressants are abruptly switched to placebo. This can cause a severe withdrawal syndrome that is easily misdiagnosed as a relapse when assessed on subjective symptom rating scales. In accordance, the findings of naturalistic long-term studies suggest that maintenance therapy has no clear benefit, and non-drug users do not show increased recurrence rates. Moreover, a growing body of evidence from hundreds of randomized controlled trials suggests that antidepressants cause suicidality, but this risk is underestimated because data from industry-funded trials are systematically flawed. Unselected, population-wide observational studies indicate that depressive patients who use antidepressants are at an increased risk of suicide and that they have a higher rate of all-cause mortality than matched controls.

Conclusion: The strong reliance on industry-funded research results in an uncritical approval of antidepressants. Due to several flaws such as publication and reporting bias, unblinding of outcome assessors, concealment and recoding of serious adverse events, the efficacy of antidepressants is systematically overestimated, and harm is systematically underestimated. Therefore, I conclude that antidepressants are largely ineffective and potentially harmful.

Citing Articles

Influence of study characteristics, methodological rigour and publication bias on efficacy of pharmacotherapy in obsessive-compulsive disorder: a systematic review and meta-analysis of randomised, placebo-controlled trials.

Cohen S, Zantvoord J, Storosum B, Mattila T, Daams J, Wezenberg B BMJ Ment Health. 2024; 27(1).

PMID: 38350669 PMC: 10862307. DOI: 10.1136/bmjment-2023-300951.


No benefit of antidepressants in inpatient treatment of depression. A longitudinal, quasi-experimental field study.

Mass R, Backhaus K, Lohrer K, Szelies M, Unkelbach B Psychopharmacology (Berl). 2023; 240(9):1963-1971.

PMID: 37526699 PMC: 10471650. DOI: 10.1007/s00213-023-06417-4.


Associations between Pharmacological Treatment Patterns during the Initial Treatment Period and the Relapse or Recurrence of Anxiety Disorders: A Nationwide Retrospective Cohort Study.

Kim J, Han C, Lee M, Jeong H, Kim J, Kim S Life (Basel). 2023; 13(5).

PMID: 37240842 PMC: 10220856. DOI: 10.3390/life13051197.


From contact coverage to effective coverage of community care for patients with severe mental disorders: A real-world investigation from Italy.

Corrao G, Monzio Compagnoni M, Barbato A, DAvanzo B, Di Fiandra T, Ferrara L Front Psychiatry. 2022; 13:1014193.

PMID: 36523868 PMC: 9744794. DOI: 10.3389/fpsyt.2022.1014193.


Biases in reporting of adverse effects in clinical trials, and potential impact on safety assessments in systematic reviews and therapy guidelines.

Westergren T, Narum S, Klemp M Basic Clin Pharmacol Toxicol. 2022; 131(6):465-473.

PMID: 36125975 PMC: 9828682. DOI: 10.1111/bcpt.13791.


References
1.
Rossler W, Ajdacic-Gross V, Riecher-Rossler A, Angst J, Hengartner M . Does menopausal transition really influence mental health? Findings from the prospective long-term Zurich study. World Psychiatry. 2016; 15(2):146-54. PMC: 4911775. DOI: 10.1002/wps.20319. View

2.
Fava G . Can long-term treatment with antidepressant drugs worsen the course of depression?. J Clin Psychiatry. 2003; 64(2):123-33. DOI: 10.4088/jcp.v64n0204. View

3.
Gartlehner G, Wagner G, Matyas N, Titscher V, Greimel J, Lux L . Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ Open. 2017; 7(6):e014912. PMC: 5623437. DOI: 10.1136/bmjopen-2016-014912. View

4.
Chen J, Papakostas G, Youn S, Baer L, Clain A, Fava M . Association between patient beliefs regarding assigned treatment and clinical response: reanalysis of data from the Hypericum Depression Trial Study Group. J Clin Psychiatry. 2011; 72(12):1669-76. DOI: 10.4088/JCP.10m06453. View

5.
Ronalds C, Creed F, Stone K, Webb S, Tomenson B . Outcome of anxiety and depressive disorders in primary care. Br J Psychiatry. 1998; 171:427-33. DOI: 10.1192/bjp.171.5.427. View